Therapeutic Targeting of RAS Mutant Cancers

— —

Edward C. Stites (Salk Inst itute for Biological Studies, La Jolla, CA) Kendra Paskvan (Pacific Northwes t University for Health Sciences, Yakima, WA)

Therapeutic Targeting of RAS Mutant Cancers

Edward C. Stites (Salk Inst itute for Biological Studies, La Jolla, CA), Kendra Paskvan (Pacific Northwes t University for Health Sciences, Yakima, WA), Shumei Kato (University of California, San Diego Moores Cancer Center)

$32.95

Paperback

Not in-store but you can order this
How long will it take?

Availability Information

We source books from suppliers in Australia and overseas. For books we don't currently have in stock, the time it takes to get them from our suppliers can vary widely - from a few days to a few months - so we check each book with each supplier to determine the expected time it will take to be supplied to us.

We then advise you accordingly. If the time taken to get any book is too long for you, you can let us know and we will cancel or adjust your order, and refund as required.

To find out the anticipated arrival time for specific items prior to ordering, please contact us by phone or email:

Phone +61 2 9264 3111, or 1800 4 BOOKS (1800 4 26657) if outside Sydney:
option 1 Abbey's Bookshop (Crime, History, Science, Kids & more) • info@abbeys.com.au
option 2 Language Book Centre (ESL & Foreign Languages) • language@abbeys.com.au
option 3 Galaxy Bookshop (Sci-fi, Fantasy, Romance, Graphic Novels) • sf@galaxybooks.com.au

QTY:

English

Cambridge University Press
15 September 2022

Oncology; Pathology; Pharmacology

Series: Elements in Molecular Oncology

Summary
Details

The KRAS oncogene is believed to be the most common single nucleotide variant oncogene in human cancer. Historically, efforts to target KRAS and the other RAS GTPases have struggled. More recently, efforts have focused on identifying and exploiting features unique to specific oncogenic mutations. This has led to the first FDA approval for a RAS targeted therapy. This new agent is a covalent inhibitor that reacts with the cysteine residue created by a codon 12 glycine to cysteine (G12C) mutation within KRAS. Mutant-specific strategies may also exist for other KRAS single nucleotide variants, and recent studies provide examples and mechanisms.

By: Edward C. Stites (Salk Inst itute for Biological Studies La Jolla CA), Kendra Paskvan (Pacific Northwes t University for Health Sciences, Yakima, WA), Shumei Kato (University of California, San Diego Moores Cancer Center)
Imprint: Cambridge University Press
Country of Publication: United Kingdom
Dimensions: Height: 228mm, Width: 152mm, Spine: 3mm
Weight: 80g
ISBN: 9781009073646
ISBN 10: 1009073648
Series: Elements in Molecular Oncology
Pages: 75
Publication Date: 15 September 2022
Audience: Professional and scholarly , Undergraduate
Format: Paperback
Publisher's Status: Active

PERHAPS A GIFT VOUCHER FOR MUM?: MOTHER'S DAY

Therapeutic Targeting of RAS Mutant Cancers

Edward C. Stites (Salk Inst itute for Biological Studies, La Jolla, CA), Kendra Paskvan (Pacific Northwes t University for Health Sciences, Yakima, WA), Shumei Kato (University of California, San Diego Moores Cancer Center)

$32.95

Paperback

See Also

Contact Abbeys

Contact Galaxy

Contact Language

Contact Us

About ABBEY'S